While one experimental vaccine appears able to reduce Ebola mortality, up until now, no drugs have been clearly demonstrated suitable for treating existing infection.
One antibody cocktail, ZMapp, initially showed promise in the field, but formal studies indicated it had less benefit than sought in preventing death.
In the PALM trial, ZMapp served as a control, meaning scientists used it as a baseline and compared the three other treatments to it.
